These include:. Arcoxia tablets should be taken once a day, preferably at the same time each day. You can take your tablet either with or without food, but if you take it without food it may start to work faster. If you have arthritis you'll usually need to take a tablet every day on a regular basis to reduce inflammation and pain. For acute gout you can take one tablet a day for up to eight days.
There are four strengths of tablet available 30 mg, 60 mg, 90 mg and mg. The strength you are prescribed depends on why you are taking the medicine:. Missed dose: If you forget to take a tablet at your usual time, take it as soon as you remember that day. If you don't remember until the following day, just leave out the forgotten dose and take your next dose as usual. Do not take a double dose to make up for a missed dose. Never take more than the dose prescribed by your doctor.
If you think this medicine is not working well enough you should make an appointment with your doctor. Medicines and possible side effects can affect individual people in different ways. The following are some of the side effects which may be associated with this medicine. Just because a side effect is listed here, this does not mean that everyone who uses this medicine will experience it, or any side effect.
If you are concerned about side-effects or experience an adverse reaction from your medicine, consult your GP. These are less likely than older NSAIDs such as naproxen and diclofenac to irritate the gut and cause side effects such as stomach ulcers. However, these side effects are still possible, particularly in elderly people. Your doctor might prescribe you a medicine to help protect your stomach if you're taking Arcoxia for long periods of time. People taking painkillers like etoricoxib have a slightly higher risk of heart problems such as fast heartbeat, chest pain, heart attack, heart failure or stroke.
These are more of a risk if you're taking a high dose of etoricoxib for a long time. If you have risk factors for heart disease or stroke, such as diabetes, high blood pressure, high cholesterol or smoking, your doctor will need to assess the overall benefits and risks before deciding if etoricoxib is suitable for you.
You should read the patient information leaflet that is supplied with your medication for more information about side effects associated with Arcoxia. You can find a copy of this here.
If you think you have experienced side effects from this medicine you can report them using the yellow card scheme. You should check with your pharmacist before taking any new medicines while you're taking etoricoxib, to make sure that the combination is safe.
Etoricoxib has not been shown to cause hepatic CYP enzyme induction in humans. Mutagenicity: Etoricoxib was found to be neither genotoxic nor mutagenic as described as follows. Etoricoxib was negative in the in vitro microbial and the TK6 human cell mutagenesis assays, with and without metabolic activation. There was no evidence of genotoxicity in the in vitro alkaline elution assay in rat hepatocytes and the in vitro chromosomal aberration assays in Chinese hamster ovary cells, with or without metabolic activation.
Significant concentrations of etoricoxib were observed in the milk of lactating rats. Use in pregnancy: As with other drugs known to inhibit prostaglandin synthesis, use of Arcoxia should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus.
However, animal reproduction studies are not always predictive of human response. There are no adequate and well-controlled studies in pregnant women. Arcoxia should be used during the first 2 trimesters of pregnancy only if the potential benefit justifies the potential risk to the fetus. Use in lactation: Etoricoxib is excreted in the milk of lactating rats. It is not known whether Arcoxia is excreted in human milk. Because many drugs are excreted in human milk and because of the possible adverse effects of drugs that inhibit prostaglandin synthesis on nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Use in children: Safety and effectiveness of etoricoxib in pediatric patients have not been established. In clinical studies, no overall differences in safety or effectiveness were observed between elderly and younger patients. Adverse Reactions. In clinical trials, Arcoxia was evaluated for safety in approximately individuals, including approximately patients with OA, RA or chronic low back pain approximately patients with OA or RA were treated for 1 year or longer.
The following drug-related adverse experiences were reported in clinical studies in patients with OA, RA or chronic low back pain treated for up to 12 weeks. The adverse experience profile was similar in patients with OA or RA treated with Arcoxia for 1 year or longer.
Seven thousand one hundred eleven patients were enrolled in an additional study in OA that compared the GI tolerability of etoricoxib 90 mg once daily 1. In the initial clinical development program, approximately patients were treated with etoricoxib 60 mg daily for 12 weeks or longer.
There was no discernible difference in the rate of serious thrombotic cardiovascular events between patients receiving etoricoxib 60 mg or non-naproxen NSAIDs. However, the rate of these events was higher in patients receiving etoricoxib compared with those receiving naproxen mg twice daily. The adverse experience profile in this study was generally similar to that reported in chronic studies in OA, RA and chronic low back pain.
In a clinical study for acute gouty arthritis, patients were treated with Arcoxia mg once daily for 8 days. In clinical studies for acute analgesia, patients were treated with Arcoxia mg once daily for days. The adverse experience profile in these studies was generally similar to that reported in the combined OA, RA and chronic low back pain studies. Psychiatric Disorders: Anxiety, insomnia, confusion, hallucinations.
Nervous System Disorders: Dysgeusia, somnolence. Cardiac Disorders: Congestive heart failure. Vascular Disorders: Hypertensive crisis.
Respiratory, Thoracic and Mediastinal Disorders: Bronchospasm. Gastrointestinal Disorders: Abdominal pain, oral and peptic ulcers including perforation and bleeding mainly in elderly patients , vomiting, diarrhea. Hepatobiliary Disorders: Hepatitis. Renal and Urinary Disorders: Renal insufficiency, including renal failure, usually reversible upon discontinuation of therapy see Precautions.
Drug Interactions. Standard monitoring of INR values should be conducted when therapy with Arcoxia is initiated or changed, particularly in the first few days, in patients receiving warfarin or similar agents. This interaction should be considered when Arcoxia is co-administered with rifampin. Methotrexate: Two studies investigated the effects of Arcoxia 60, 90 or mg administered once daily for 7 days in patients receiving once-weekly methotrexate doses of 7. Arcoxia at 60 mg and 90 mg had no effect on methotrexate plasma concentrations as measured by AUC or renal clearance.
In one study, Arcoxia mg had no effect on methotrexate plasma concentrations as measured by AUC or renal clearance. This interaction should be given consideration in patients taking Arcoxia concomitantly with these products. This interaction should be given consideration in patients taking Arcoxia concomitantly with lithium.
Aspirin: Arcoxia can be used concomitantly with low-dose aspirin at doses for cardiovascular prophylaxis. However, concomitant administration of low-dose aspirin with Arcoxia results in an increased rate of GI ulceration or other complications compared to use of Arcoxia alone. At steady-state, etoricoxib mg once daily had no effect on the antiplatelet activity of low-dose aspirin 81 mg once daily.
Oral Contraceptives: Arcoxia 60 mg given concomitantly with an oral contraceptive containing 35 mcg ethinyl estradiol EE and 0. This increase in EE concentration should be considered when selecting an oral contraceptive for use with etoricoxib.
An increase in EE exposure can increase the incidence of adverse events associated with oral contraceptives eg, venous thromboembolic events in women at risk. Hormone Replacement Therapy: Administration of Arcoxia mg with hormone replacement therapy consisting of conjugated estrogens 0.
The effect of the recommended chronic doses of Arcoxia 60 mg and 90 mg has not been studied. The effects of Arcoxia mg on the exposure AUC hr to these estrogenic components of Premarin were less than half of those observed when Premarin was administered alone and the dose was increased from 0. The clinical significance of these increases is unknown and higher doses of Premarin were not studied in combination with Arcoxia. These increases in estrogenic concentration should be taken into consideration when selecting postmenopausal hormone therapy for use with Arcoxia.
Antacids and ketoconazole a potent inhibitor of CYP3A4 did not have clinically important effects on the pharmacokinetics of Arcoxia. MIMS Class. Never take more than the prescribed dose. If you suspect that you or someone else might have taken an overdose of this medicine, go to the accident and emergency department of your local hospital.
Take the container with you, even if it is empty. This medicine is for you. Never give it to other people even if their condition appears to be the same as yours. Do not keep out-of-date or unwanted medicines. Take them to your local pharmacy which will dispose of them for you. Dated July Had partial left shoulder tear. It no longer hurt and I was able to do some things but not what I had been doing.
Doctor suggested stem cells and prp. Had it a month ago and am I constant pain and it Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Egton Medical Information Systems Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy.
Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
0コメント